Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital Says

FDA Breifing Documents for Regeneron's (REGN) Praluent 'Read Well,' Says RBC Capital

June 5, 2015 9:35 AM EDT

RBC Capital maintained an Outperform on Regeneron Pharma (NASDAQ: REGN). Earlier the FDA posted briefing docs for Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK-9 drug Praluent. In the view of analyst Adnan Butt, FDA documents "read well."

"Overall conclusions... More